Clinical trials: Head Neck Cancer Squamous Cell Recurrent
Head and Neck Squamous Cell Carcinoma
SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody（SCT200）and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous…
- Trial name
- NCT03744208
- Testing
- Anti-EGFR monoclonal antibody
- Volunteers
- 30 people
- Sponsor
- Shi Yuankai
Squamous Cell Carcinoma of the Head and Neck
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
This is a retrospective international, multi-center, non-interventional cohort study based on use of data derived from established medical records and secondary analysis of archival tumor samples.
- Trial name
- SUPREME-HN (NCT02543476)
- Where
- 18 sites in United States, Germany and 5 more
- Volunteers
- 412 people
- Sponsor
- AstraZeneca
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06662058
- Testing
- Audiometric Test, Interview
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Emory University
Recurrent Head and Neck Squamous Cell Carcinoma
Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to determine whether a perioperative PD-1 antibody-based treatment strategy, consisting of neoadjuvant PD-1 antibody plus chemotherapy followed by adjuvant PD-1 antibody after surgery, improves…
- Trial name
- neo-Recur (NCT07751289)
- Testing
- Neoadjuvant PD-1 antibody plus chemotherapy, surgery, Adjuvant PD-1 antibody
- Volunteers
- 217 people
- Sponsor
- Yanjie Zhang, MD
Head and Neck Cancer
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
The goal of this clinical research study is to learn if giving the new drug, Tarceva® (OSI-774), in combination with Platinol® (cisplatin) and Taxotere® (docetaxel) is effective in the treatment of metastatic or recurrent head…
- Trial name
- NCT00076310
- Testing
- Docetaxel, OSI-774, Cisplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Cancer of the Head and Neck
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
The standard treatment for head and neck cancer relapses in previously irradiated patients is controversial. Reirradiation has had some success, but many patients still die from their disease.
- Trial name
- NCT00934518
- Testing
- Radiation, Cetuximab
- Where
- United States
- Sponsor
- Milton S. Hershey Medical Center
Squamous Cell Carcinoma Of The Head And Neck
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached…
- Trial name
- NCT01488318
- Testing
- Cetuximab, Dasatinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Julie E. Bauman, MD, MPH
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Head and Neck Squamous Cell Carcinoma
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous…
- Trial name
- NCT06308913
- Testing
- INCB081776, Pembrolizumab, Palliative RT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
- Trial name
- NCT00021424
- Testing
- recombinant fowlpox-TRICOM vaccine
- Where
- United States
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and…
- Trial name
- NCT04868162
- Testing
- MRG003, MRG003+HX008
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Head and Neck Squamous Cell Carcinoma
REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors
Each subject will participate in the trial until death, drop out, or loss-to follow-up from the time the subject signs the Informed Consent Form (ICF) through the final contact.
- Trial name
- REPORT (NCT03317327)
- Testing
- Nivolumab, Radiotherapy (RT)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Human Papilloma Virus
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV Deoxyribonucleic Acid (DNA) vaccine in combination…
- Trial name
- NCT03162224
- Testing
- MEDI0457, CELLECTRA®5P device, Durvalumab
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- MedImmune LLC
Esophageal Cancer
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or…
- Trial name
- NCT06769113
- Testing
- HLX43
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Henlius Biotech
Head and Neck Squamous Cell Carcinoma
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of the study is to evaluate the comparability of efficacy, safety, and immunogenicity of RPH-002 and Erbitux® when administered in combination with docetaxel and cisplatin as first-line therapy in patients…
- Trial name
- NCT07435324
- Testing
- RPH-002, Erbitux®, Cisplatin
- Where
- 34 sites in Russia, Uzbekistan
- Volunteers
- 161 people
- Sponsor
- R-Pharm
Esophageal Squamous Cell Carcinoma
Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)
This is a phase 2 trial investigating the effect and safety of afatinib in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.
- Trial name
- NCT03940976
- Testing
- Afatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Head and Neck Cancer, Head and Neck Cancer Squamous Cell Carcinoma
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
This study is a prospective,open-label,single-arm clinical trial to evaluate the efficacy and safety of s Surufatinib combined with envolizumab as second-line treatment of recurrent/metastatic head and neck squamous cell…
- Trial name
- HNSCC (NCT06876844)
- Testing
- combination of Surufatinib and Envolizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00513435
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
This phase Ib trial tests the safety, side effects and how well losartan, pembrolizumab and stereotactic body radiation therapy (SBRT) for the treatment of patients with head and neck squamous cell carcinoma that has come back to…
- Conditions
- Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06211335
- Testing
- Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of California, Davis